Rowlandmiller & PARTNERS.ADV Sells 185 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Rowlandmiller & PARTNERS.ADV lowered its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 21.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 668 shares of the medical research company’s stock after selling 185 shares during the quarter. Rowlandmiller & PARTNERS.ADV’s holdings in Bio-Rad Laboratories were worth $163,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Bio-Rad Laboratories by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 1,919,808 shares of the medical research company’s stock valued at $630,676,000 after buying an additional 12,168 shares in the last quarter. Wealthfront Advisers LLC bought a new stake in shares of Bio-Rad Laboratories during the fourth quarter worth approximately $342,686,000. Dimensional Fund Advisors LP increased its stake in Bio-Rad Laboratories by 14.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 746,119 shares of the medical research company’s stock valued at $245,106,000 after purchasing an additional 91,690 shares in the last quarter. Earnest Partners LLC increased its stake in Bio-Rad Laboratories by 2.1% in the fourth quarter. Earnest Partners LLC now owns 618,049 shares of the medical research company’s stock valued at $203,035,000 after purchasing an additional 12,500 shares in the last quarter. Finally, Ariel Investments LLC increased its stake in Bio-Rad Laboratories by 48.0% in the fourth quarter. Ariel Investments LLC now owns 560,524 shares of the medical research company’s stock valued at $184,138,000 after purchasing an additional 181,829 shares in the last quarter. Institutional investors own 65.24% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Citigroup lowered their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Wells Fargo & Company lowered their price objective on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an “equal weight” rating for the company in a research report on Monday. Royal Bank of Canada lowered their price objective on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an “outperform” rating for the company in a research report on Friday, May 2nd. UBS Group lowered their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Finally, Wall Street Zen downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $324.25.

Bio-Rad Laboratories Stock Performance

Shares of BIO stock opened at $230.36 on Wednesday. The stock has a market cap of $6.27 billion, a P/E ratio of -3.54 and a beta of 0.93. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. The company has a fifty day moving average price of $236.07 and a two-hundred day moving average price of $283.95. Bio-Rad Laboratories, Inc. has a one year low of $211.43 and a one year high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.73 by $0.81. The company had revenue of $585.40 million during the quarter, compared to analysts’ expectations of $573.01 million. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Bio-Rad Laboratories’s quarterly revenue was down 4.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.30 EPS. As a group, equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.